TrialArthritis and rheumatism2011

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.

Dinesh Khanna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.